Pharmaceutical sales were up by 32% to Rs. 298 crores as compared to Q4 FY20 whereas Crop Protection sales was up by 54% at Rs. 235 crores as compared to Q4 FY20
Entire term loan of Rs. 35 crores was availed by its group company Insunt Trading Private Limited from the Aditya Birla Finance Ltd.
Net income rose on a consolidated basis to Rs 2,221.42 crore during the fourth quarter of 2020-21
This EoI conveys our intention to submit an all-cash voluntary tender offer for its entire share capital at a price of EUR 17.30 per share
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
This year marks the start of a new era of growth for Arkema
The consolidated order backlog as on March 31, 2021 stood at Rs. 1,748 crore which comprised 85% domestic orders and 15% international orders
The facility is expected to be completed in 2024
The emerging markets posted organic sales growth of 18.5 percent in the first quarter whereas organic sales development in the mature markets was positive at 0.5 percent
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
Solvay is investing in Invizius, a biotechnology start-up in the United Kingdom that is developing an anti-inflammatory solution for haemodialysis
The separation is expected to be completed by early Q3
SRF’s revenues rose 40% YoY to Rs26bn driven by higher realisation in packaging film business and technical textiles
Sales in all segments returned to year over year growth
MCC has decided to transfer all shares of SMP held by PCRIJ to Sinopec around the end of October 2021
The strong recovery of materials business at the end of last year has continued into Q1
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The review is consistent with Croda’s prioritisation of investments in faster-growth life science and consumer markets which now represent over 80% of the Group’s profitability
FMC first quarter adjusted EBITDA was $307 million, a decrease of 14 percent from the prior-year period
Subscribe to our newsletter & stay updated.
_195_291.jpg)
